STAT3 and cancer: Phase I/II studies on the use of STA-21 for the treatment of psoriatic lesions and on OPB-31121 and OPB-51602 for the treatment of advanced cancers have been completed, revealing that all of these compounds are effective inhibitors of STAT3 phosphorylation and have acceptable safety profiles.